Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration

被引:41
作者
Dirani, All
Ambresin, Aude
Marchionno, Laetitia
Decugis, Doris
Mantel, Irmela
机构
[1] Univ Lausanne, Dept Ophthalmol, CH-1000 Lausanne 7, Switzerland
[2] Fdn Asile Aveugles, Jules Gonin Eye Hosp, Lausanne, Switzerland
关键词
ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL AFLIBERCEPT; VISUAL-ACUITY; ANATOMICAL OUTCOMES; FACTOR VEGF; RANIBIZUMAB; EYES; BEVACIZUMAB; EXPRESSION;
D O I
10.1016/j.ajo.2015.06.025
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To study the effect of various baseline factors, particularly the type of drug (ranibizumab vs aflibercept), on the functional and anatomic response of treatment-naive pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (neovascular AMD), after 3 intravitreal injections. DESIGN: Retrospective consecutive case series. METHODS: This study included 102 patients (n = 115 eyes) with treatment-naive neovascular AMD and PED ( > 150 mu m), who were treated with either ranibizumab (n = 68 eyes) or aflibercept (n = 47 eyes). A multivariate analysis using stepwise linear regression was performed in order to assess factors influencing visual acuity improvement, as well as treatment response of PED height after 3 monthly injections. RESULTS: Multivariate analysis revealed that better visual improvement was associated with lower best-corrected visual acuity (BCVA) at baseline (P = .001), presence of subretinal fluid (P = .001), and retinal angiomatous proliferation (P = .001); PED reduction was associated with higher PED at baseline (P = .001), predominantly serous PED (P = .003), and the use of aflibercept (P = .022). Drug type was not associated with change in BCVA at 3 months. CONCLUSION: Eyes with neovascular AMID and PED showed significant functional and anatomic response after 3 monthly intravitreal anti-VEGF injections. The functional response depended on baseline BCVA, presence of subretinal fluid, and retinal angiomatous proliferation, while anatomic response was influenced by baseline PED height, degree of vascularization, and drug type. Drug type was not associated with change in BCVA, but had a weak effect on anatomic response. (C) 2015 by Elsevier Inc. All rights reserved.
引用
收藏
页码:732 / 738
页数:7
相关论文
共 36 条
[1]   Two-Year Course of Subfoveal Pigment Epithelial Detachment in Eyes with Age-Related Macular Degeneration and Visual Acuity Better than 20/40 [J].
Baba, Takayuki ;
Kitahashi, Masayasu ;
Kubota-Taniai, Mariko ;
Oshitari, Toshiyuki ;
Yamamoto, Shuichi .
OPHTHALMOLOGICA, 2012, 228 (02) :102-109
[2]   Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab [J].
Bakall, Benjamin ;
Folk, James C. ;
Boldt, H. Culver ;
Sohn, Elliott H. ;
Stone, Edwin M. ;
Russell, Stephen R. ;
Mahajan, Vinit B. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 156 (01) :15-22
[3]   Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment [J].
Bolz, Matthias ;
Michels, Stephan ;
Geitzenauer, Wolfgang ;
Prager, Franz ;
Schmidt-Erfurth, Ursula .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (06) :785-789
[4]   Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid [J].
Bottomley, MJ ;
Webb, NJA ;
Watson, CJ ;
Holt, L ;
Bukhari, M ;
Denton, J ;
Freemont, AJ ;
Brenchley, PEC .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 119 (01) :182-188
[5]   Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].
Brown, David M. ;
Kaiser, Peter K. ;
Michels, Mark ;
Soubrane, Gisele ;
Heier, Jeffrey S. ;
Kim, Robert Y. ;
Sy, Judy P. ;
Schneider, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444
[6]   Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related Macular Degeneration [J].
Chang, Andrew A. ;
Li, Haitao ;
Broadhead, Geoffrey K. ;
Hong, Thomas ;
Schlub, Timothy E. ;
Wijeyakumar, Wijeyanthy ;
Zhu, Meidong .
OPHTHALMOLOGY, 2014, 121 (01) :188-192
[7]   Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab [J].
Cho, Hyung ;
Shah, Chirag P. ;
Weber, Marissa ;
Heier, Jeffrey S. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (08) :1032-1035
[8]   Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration [J].
Gharbiya, Magda ;
Iannetti, Ludovico ;
Parisi, Francesco ;
De Vico, Umberto ;
Mungo, Maria Laura ;
Marenco, Marco .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[9]   Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results [J].
Grewal, D. S. ;
Gill, M. K. ;
Sarezky, D. ;
Lyon, A. T. ;
Mirza, R. G. .
EYE, 2014, 28 (07) :895-899
[10]   Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration [J].
Heier, Jeffrey S. ;
Brown, David M. ;
Chong, Victor ;
Korobelnik, Jean-Francois ;
Kaiser, Peter K. ;
Quan Dong Nguyen ;
Kirchhof, Bernd ;
Ho, Allen ;
Ogura, Yuichiro ;
Yancopoulos, George D. ;
Stahl, Neil ;
Vitti, Robert ;
Berliner, Alyson J. ;
Soo, Yuhwen ;
Anderesi, Majid ;
Groetzbach, Georg ;
Sommerauer, Bernd ;
Sandbrink, Rupert ;
Simader, Christian ;
Schmidt-Erfurth, Ursula .
OPHTHALMOLOGY, 2012, 119 (12) :2537-2548